Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
- PMID: 16442208
- DOI: 10.1016/j.eururo.2005.12.031
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
Abstract
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.
Methods: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.
Results: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.
Conclusions: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.
Comment in
- 
  
  Re: Richard J. Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck, J. Alfred Witjes, Christian Bouffioux, Louis Denis and Donald W.W. Newling. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.Eur Urol. 2006 Sep;50(3):623-4; author reply 624-5. doi: 10.1016/j.eururo.2006.04.005. Epub 2006 May 4. Eur Urol. 2006. PMID: 16707208 No abstract available.
- 
  
  Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications.Eur Urol. 2011 Oct;60(4):721-3. doi: 10.1016/j.eururo.2011.07.065. Epub 2011 Aug 5. Eur Urol. 2011. PMID: 21840119 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        